The roller-coaster-like trajectory that has been Co-Diagnostics ' (NASDAQ: CODX) stock price climbed another hill on Thursday. The healthcare-testing specialist's shares closed over 21% higher on the day, due largely to news of a fresh patent awarded to the company.
Co-Diagnostics announced that its CoPrimer diagnostics platform, which underpins testing products -- like its popular-for-obvious-reasons Logix Smart for COVID-19 -- has been granted a patent in South Korea. This bolsters the intellectual-property protection of CoPrimer, which received a U.S. patent in 2018.
Image source: Getty Images.
For further details see:
Why Co-Diagnostics Blasted 21% Higher on Thursday